RPRX
Royalty Pharma plc38.38
-0.15-0.39%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Cap alloc tilts to royalties; pipeline reaffirmed.
Q&A largely reaffirmed Royalty Pharma's prepared growth narrative and 3%-8% 2026 royalty receipts guidance, but management detailed a dynamic capital allocation now biased toward royalties over buybacks amid pipeline strength. They eased CF concerns, confirming gradual Alyftrek conversion tracked expectations with 7% franchise royalty growth in 2025. Pipeline diversity shone through, with LP(a) delays unsurprising, non-obstructive HCM upside, and aggregate $2.1B peak royalties eyed. China team expansion imminent. Confident tone persists; investors track pivotal readouts.
Key Stats
Market Cap
22.38BP/E (TTM)
21.93Basic EPS (TTM)
1.75Dividend Yield
0.02%Recent Filings
8-K
Q4 Receipts up 18%
Royalty Pharma reported Q4 2025 Portfolio Receipts of $874M, up 18% year-over-year, and full-year $3,254M, up 16%, fueled by Voranigo, Trelegy, Tremfya, and cystic fibrosis royalties despite Promacta generics. Deployed $2.6B on royalties including daraxonrasib; repurchased $1.2B shares. Guides 2026 Portfolio Receipts to $3.275B-$3.425B. Cash flows strong.
10-K
FY2025 results
Royalty Pharma generated $3.3B Portfolio Receipts in FY2025 ended December 31, 2025, up 16% y/y, fueled by cystic fibrosis franchise growth to $917M (7% y/y) and strong launches like Voranigo ($118M) and Imdelltra ($10M), while Trelegy rose 17% y/y to $332M. Q4 momentum shone through 13% y/y Royalty Receipts growth to $3.1B annually, with Vertex, GSK, and J&J products driving acceleration amid global demand. Yet margins faced Medicare redesign pressures on Imbruvica and Promacta. Deployed $2.6B in royalties including $885M on Imdelltra; repurchased $1.2B shares, paid $512M dividends. Debt hit $9.2B at year-end with $1.8B revolver available. Biopharma sales risks loom large.
8-K
MYQORZO FDA approval unlocks royalties
FDA approved Cytokinetics' MYQORZO for oHCM on December 19, 2025, triggering Royalty Pharma's 4.5% royalty on sales up to $5B, then 1%. Royalty Pharma funded $225M fully drawn in 2022 and $50M of $225M in 2024, securing $523M repayments over 10 years. Cytokinetics can draw another $175M soon. Royalties hinge on sales ramp.
8-K
CLO Lloyd exits, McGivern steps up
Royalty Pharma's Executive VP and Chief Legal Officer George W. Lloyd steps down effective December 31, 2025, shifting to senior advisor. Arthur R. McGivern, current Executive VP and General Counsel since October 2022, assumes the role January 1, 2026. Smooth transition. Lloyd's executive offer letter terminates as planned.
8-K
Q3 receipts +11%, guidance raised
Royalty Pharma reported Q3 2025 Portfolio Receipts up 11% to $814 million, driven by Voranigo, Tremfya, and cystic fibrosis royalties. Active deals added royalties on Imdelltra (up to $950M), obexelimab (up to $300M), and Amvuttra ($310M), with $1B capital deployment in the quarter. Raised full-year guidance to $3.2B-$3.25B, implying 14-16% growth. Shares repurchased: $152M.
IPO
Sector
Industry
BLRX
BioLineRx Ltd.
3.01-0.17
CNTB
Connect Biopharma Holdings Limi
2.36+0.06
CPMD
Cannapharmarx Inc.
0.00-0.00
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
RAPH
RAPHAEL PHARMACEUTICAL INC
1.40+0.00
RGBP
Regen Biopharma, Inc.
0.01-0.00
RVPH
Reviva Pharmaceuticals Holdings
0.64+0.01
SPRY
ARS Pharmaceuticals, Inc.
10.66+0.07
VOXR
Vox Royalty Corp.
5.04-0.29
XOMA
XOMA Royalty Corporation
25.83+0.34